Colin, living with acute hepatic porphyria
Alnylam Advocacy Imperatives
Actively listen to patients and integrate their perspectives across our business
Engage, empower and inspire advocacy groups to meet the needs of patient communities
Support and partner on patient education and disease awareness programs
Patient Advocacy Around the World
Working in more than 20 countries with over 60 Patient Advocacy Groups (PAGs)
ADVOCACY GROUP LEGEND:
Patient Advocacy at Alnylam
Patient Advocacy and Engagement Team
Meet the Patient Advocacy & Engagement Team
Vice President
Cambridge, MA
Senior Director,
CEMEA Region
Maidenhead, UK
Associate Director,
Asia Pacific Region
Tokyo, Japan
Director,
Primary Hyperoxaluria Type 1
Cambridge, MA
Director,
Amyloidosis
Cambridge, MA
Associate Director,
CEMEA Region
Maidenhead, UK
Meet the Patient Advocacy & Engagement Team
Vice President
Cambridge, MA
Senior Director,
CEMEA Region
Maidenhead, UK
Associate Director,
Asia Pacific Region
Tokyo, Japan
Director,
Primary Hyperoxaluria Type 1
Cambridge, MA
Director,
Amyloidosis
Cambridge, MA
Associate Director,
CEMEA Region
Maidenhead, UK
A global grant program that empowers patient advocacy groups to develop innovative solutions to address the unmet needs for the communities they serve.
Get in touch with us at: patientadvocacy@alnylam.com
Understanding RNAi
RNA interference (RNAi) is the core discovery that forms the therapies Alnylam is developing. It is recognized as a major scientific breakthrough—but how does it work, exactly?
Learn About How RNAi-Based Medicines Work